Worth a closer look
- Open-market purchase with their own money (Form 4 code P), not a grant or option exercise.
- Raised their own holding by 221%.
Reasons for caution
- Held indirectly (a trust, fund or family entity), so the economic owner isn't only the named insider.
- Similar past buys beat the S&P 500 only 45% of the time (719 cases); the typical one trailed it by 1.5%.
- Their past buys: only 0 of 5 beat the S&P 500.
What happened after this filing
Insider Twins: past buys with the same traits
2 insiders buying · no CEO or CFO
BLNK Sep 2, 2020 +201.4% vs S&PCVNA Apr 3, 2020 +153.6% vs S&PCATX Feb 1, 2024 +107.3% vs S&PATXI Sep 12, 2023 -86.8% vs S&PPMN Mar 6, 2026 -71.3% vs S&PLYEL Mar 9, 2026 -62.1% vs S&PWhat we couldn't check
- Why they traded. Filings don't say, and we don't guess.
- Company news after the filing, and any private terms.
Orbimed Advisors LLC (a director) bought $20M of WWB at about $17.00 on Nov 16, 2026, reported to the SEC on Nov 18, 2026. Buys like this beat the S&P 500 45% of the time since 2020, against 46% for all insider buys. We found 2 points that make it worth a closer look and 3 reasons for caution. History, not a prediction.
Following. We'll keep this page updated; see everything you follow. Want an email when the 30 and 90-day results land? Use the WWB alerts below.
Get this week's insider report
The week's biggest insider buys, every new cluster buy and the stocks to watch, in one printable PDF. Plus the free Monday email.
Check your inbox to confirm, so you get next week's report too.
Written by fixed rules from SEC filings and our measured history, not by an AI model. Public data only. History, not a prediction, and not investment advice.